PHARMECO June 25 Webinar series - Webinar 1 - From SSbD to pilot scale

The presentation discusses the PHARMECO project, a public-private partnership aimed at advancing Safe and Sustainable by Design (SSbD) practices in pharmaceutical manufacturing. The project focuses on improving sustainable practices in the manufacturing of small molecules, biologics, and peptides, as well as decontamination. It involves implementing process optimizations and technological innovations at various stages of pharmaceutical manufacturing and standardized sustainability assessment methods.

The PHARMECO consortium consists of 31 international partners, including major pharmaceutical and medtech companies, research institutions, government bodies, and SMEs from 14 different countries. The project is coordinated by Ghent University (Belgium) and led by Sanofi (Germany), with a budget of 45 million euros, co-funded by the European Union and private members of the IHI JU. The project duration is from November 1, 2024, to October 31, 2030.

The presentation is structured around the questions "Why? What? Who? How?" and includes interventions from Sarah Costers (Ghent University, Belgium), William Mackintosh (RISE, Sweden), and Bruno Baillon (Sanofi, France) 2. The key objectives of PHARMECO include integrating SSbD, developing sustainability steering tools, implementing sustainable manufacturing solutions, and standardized sustainability assessments.

The overall work plan structure involves sustainable technology platforms and sector-wide collaboration to achieve the project's goals. The presentation also highlights the impact of PHARMECO, such as improved sustainability practices, reduced environmental impact, adherence to global environmental and sustainability standards, and advances in global SDGs.